Vadodara based drugmaker Alembic has posted a 63.8 per cent rise in net profit for the second quarter of the fiscal to Rs 21.77 crore primarily on robust sales growth in branded formulations and active pharmaceutical ingredients (APIs).Net sales for the quarter stood at Rs 363 crore.
The company's domestic branded formulations business grew 27 per cent on a year-on-year basis to Rs 207 crore in Q2 while the APIs segment posted a 33 per cent rise to Rs 100 crore. Alembic's generics business reported a modest rise of 10 per cent in sales to Rs 40 crore during the quarter, it said in a statement. Its key products Azithral, Wikoryl and Zeet registered a growth of more than 26 per cent each during July-September.
